14 Sep

AstraZeneca and Australia Government announce supply agreement for COVID-19 vaccine

AstraZeneca has signed an agreement with the Australian Government to supply approximately 34 million doses of its COVID-19 vaccine candidate, AZD1222, should ongoing clinical trials prove successful.

Country President of AstraZeneca Australia & New Zealand, Liz Chatwin, said: “Further to our agreement with Government, we have finalised arrangements with CSL to manufacture approximately 30 million doses of AZD1222 in Australia, in addition to 3.8 million doses sourced from overseas. “Approximately 34 million doses will be supplied to the Australian Government, reflecting AstraZeneca’s global commitment to ensure broad and equitable access to this vaccine against COVID-19, at no profit during the pandemic.”

The first doses are expected to be available in the first quarter of 2021, with the remaining 30 million doses produced by CSL over the following months. Final delivery is due by September 2021. AstraZeneca is currently conducting clinical trials to assess the safety and efficacy of AZD1222, in collaboration with Oxford University, to protect against COVID-19.
AstraZeneca continues to engage with governments, multilateral organisations and partners around the world to ensure broad and equitable access to the vaccine, should clinical trials prove successful. The agreement with the Australian Government takes the global supply capacity towards three billion doses of the vaccine. 

About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and www.astrazeneca.com.au.

Melissa Millard
Head of Communications, AstraZeneca Australia & New Zealand
+61 438 757 568

Posted in General by Anonymous

Leave a comment